NASDAQ:DFTX Definium Therapeutics (DFTX) Stock Price, News & Analysis $32.08 -0.92 (-2.79%) As of 11/13/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Definium Therapeutics Stock (NASDAQ:DFTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Definium Therapeutics alerts:Sign Up Key Stats Today's Range$31.47▼$32.7050-Day Range$30.36▼$40.3252-Week Range$10.46▼$49.70Volume777,628 shsAverage Volume1.70 million shsMarket Capitalization$4.31 billionP/E RatioN/ADividend YieldN/APrice Target$66.24Consensus RatingModerate Buy Company Overview Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. AI Generated. May Contain Errors. Read More Definium Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreDFTX MarketRank™: 3.167908983915 of 5 starsDefinium Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 311th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingDefinium Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 1 strong buy rating, 19 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDefinium Therapeutics has a consensus price target of $66.24, representing about 106.5% upside from its current price of $32.08.Amount of Analyst CoverageDefinium Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Definium Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Definium Therapeutics are expected to grow in the coming year, from ($2.94) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Definium Therapeutics is -10.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Definium Therapeutics is -10.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDefinium Therapeutics has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.33% of the float of Definium Therapeutics has been sold short.Short Interest Ratio / Days to CoverDefinium Therapeutics has a short interest ratio ("days to cover") of 5.77.Change versus previous monthShort interest in Definium Therapeutics has recently decreased by 4.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDefinium Therapeutics does not currently pay a dividend.Dividend GrowthDefinium Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.53 News SentimentDefinium Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Definium Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 11 people have searched for DFTX on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Definium Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Definium Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,626,115.00 in company stock.Percentage Held by Insiders2.40% of the stock of Definium Therapeutics is held by insiders.Percentage Held by Institutions27.91% of the stock of Definium Therapeutics is held by institutions.Read more about Definium Therapeutics' insider trading history. Receive DFTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Definium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DFTX Stock News HeadlinesWall Street Zen Upgrades Definium Therapeutics (NASDAQ:DFTX) to "Hold"2 minutes ago | americanbankingnews.comDefinium Therapeutics Announces Investor Conference ParticipationNovember 12 at 2:36 PM | theglobeandmail.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations. | Monument Traders Alliance (Ad)Is Definium Therapeutics (DFTX) Fully Priced After Positive Phase 3 Results?November 12 at 9:35 AM | finance.yahoo.comDefinium Therapeutics Announces Planned Third-Quarter Results WebcastNovember 11 at 7:09 PM | theglobeandmail.comDefinium Therapeutics (DFTX) Following DT120 Phase 3 Data Is The Undervalued Story IntactNovember 11 at 7:09 PM | finance.yahoo.comBank of America Securities Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)November 11 at 9:08 AM | theglobeandmail.comRBC Raises Price Target on Definium Therapeutics to $70 From $66, Keeps Outperform, Speculative RiskNovember 10, 2026 | marketscreener.comMSee More Headlines DFTX Stock Analysis - Frequently Asked Questions How have DFTX shares performed this year? Definium Therapeutics' stock was trading at $13.39 at the start of the year. Since then, DFTX shares have increased by 139.6% and is now trading at $32.08. How were Definium Therapeutics' earnings last quarter? Definium Therapeutics, Inc. (NASDAQ:DFTX) posted its quarterly earnings data on Monday, November, 9th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.09. Read the conference call transcript. When did Definium Therapeutics' stock split? Shares of Definium Therapeutics reverse split on Monday, August 29th 2022.The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Definium Therapeutics' major shareholders? Top institutional investors of Definium Therapeutics include State Street Corp (2.46%), Candriam S.C.A. (0.38%), Russell Investments Group Ltd. (0.25%) and Royce & Associates LP (0.19%). Insiders that own company stock include Robert Barrow, Mark Sullivan, Daniel Karlin, Brandi Roberts, Matthew T Wiley, Dan Karlin, Schond L Greenway, Carrie Liao and David W Gryska. View institutional ownership trends. How do I buy shares of Definium Therapeutics? Shares of DFTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Definium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Definium Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Advanced Micro Devices (AMD), Intel (INTC), Compass Pathways (CMPS) and NIO (NIO). Company Calendar Last Earnings11/09/2026Today11/13/2026Jefferies Global Healthcare Conference11/17/20269th Annual Evercore ISI HealthCONx Conference12/01/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, DFTX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DFTX Previous SymbolNASDAQ:MNMD CIK1813814 Webmindmed.co Phone212 220 6633FaxN/AEmployees40Year Founded2019Price Target and Rating Average Price Target for Definium Therapeutics$66.24 High Price Target$90.00 Low Price Target$25.00 Potential Upside/Downside+106.5%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.23% Return on Assets-43.90% Debt Debt-to-Equity Ratio0.04 Current Ratio15.53 Quick Ratio6.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book4.46Miscellaneous Outstanding Shares134,370,000Free Float131,142,000Market Cap$4.31 billion OptionableOptionable Beta2.23 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:DFTX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Definium Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Definium Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DFTX Stock Alerts